Table 2. Genotype frequencies of CRP SNP rs7553007 in metastatic CRC patients.
| SNP | ||||
| Total cancer | Control | P valuea | P valueb | |
| (n = 228) | (n = 149) | |||
| AA | 70 (30.7%) | 47 (31.5%) | 0.857 | |
| AG | 113 (49.6%) | 76 (51.0%) | ||
| GG | 45 (19.7%) | 26 (17.4%) | ||
| AA vs. (AG/GG) | 0.579 | |||
| (AA/AG) vs. GG | 0.863 | |||
| Synchronous | ||||
| (n = 142) | ||||
| AA | 40 (28.2%) | 0.605 | 0.441 | |
| AG | 71 (50.0%) | |||
| GG | 31 (21.8%) | |||
| AA vs. (AG/GG) | 0.347 | 0.307 | ||
| (AA/AG) vs. GG | 0.530 | 0.287 | ||
| Metachronous | ||||
| (n = 86) | ||||
| AA | 30 (34.9%) | 0.869 | ||
| AG | 42 (48.8%) | |||
| GG | 14 (16.3%) | |||
| AA vs. (AG/GG) | 0.818 | |||
| (AA/AG) vs. GG | 0.599 |
NOTE. aGroups were compared for differences in patients (total cancer, synchronous, or metachronous) and control subjects.
b
Groups were compared for differences in different (synchronous and metachronous) patients.